Clinical Trial

Fabhalta Capsules Specified Drug-use Survey

Active, Not Recruiting
View on ClinicalTrials.gov →
Summary
The objective of this study is to evaluate the safety and effectiveness of Fabhalta in patients with C3 glomerulopathy in clinical practice.
Protocol Amendment History 4 changes
critical Trial status changed: Recruiting → Active, Not Recruiting 2026-06-24
notable Enrollment reduced: 50 -> 32 participants 2026-06-24
notable Trial sites expanded: 26 -> 30 locations 2026-06-02
notable Trial sites expanded: 23 -> 26 locations 2026-04-14
Trial Details
NCT Number NCT07156149
Lead Sponsor Novartis Pharmaceuticals
Conditions C3 Glomerulopathy
Enrollment 33 participants
Start Date 2025-09-17
Primary Completion 2028-06-30 (estimated)
Study Completion 2028-06-30 (estimated)
Updated on ClinicalTrials.gov 2026-07-13